Published in Women's Health Weekly, August 3rd, 2000
According to these researchers, this growth factor variant might also be significant for the development of breast cancer.
"Epidermal growth factor receptor vIII (EGFRvIII) is a tumor-specific, ligand-independent, constitutively active variant of the EGFR," explained C.K. Tang et al. ("Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer," Cancer Res, 2000;60(11):3081-3087).
To test this receptor's...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly